Truist analyst Richard Newitter kept the Buy rating on the shares and lowered the firm’s price target on Treace Medical to $30 from $33. The company’s Q2 results were “solid” with 40% growth and a long runway into the $2B total addressable market, but the stock’s valuation accurately reflects its growth profile, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TMCI:
- Treace Medical raises FY23 revenue view to $191M-$197M from $190M-$196M
- Treace Medical reports Q2 EPS (20c), consensus (24c)
- Treace Announces Participation in the UBS Medtech, Tools and Genomics Summit 2023
- Treace to Report Second Quarter 2023 Financial Results on August 8, 2023
- Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer